tbuckley/cabot-search huggingface dataset:
Hyperactive children
Authors: B. Bond
Journal: JAMA (1978)

INVARIABLY, when Bobby Smith arrives in the pediatric clinic, there is wailing and gnashing of teeth, followed by the frantic scurrying of staff members into the relative safety of their offices. So great are Bobby's clamorings and his mother's multidecibel response that a staff member once joked that we needed an exorcist on the staff, not another pediatrician. Having dealt with Mrs Smith's difficulties in managing her son's behavior for several months, we were not surprised by her recent announcement, "I have been reading the papers. Bobby is hyperactive and I want medication for it." A thorough exploration of Bobby's symptoms and environment failed to confirm her diagnosis. Nevertheless, Bobby's case illustrates the confusion that surrounds the hyperkinetic syndrome and the complexities of its manifestations and diagnosis. As hyperactivity has gained notoriety in the press, it has come to rival teething as today's scapegoat for anything from tremors to tantrums.
Annual Reports
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reports of Societies
Authors: D Guy, Dain Thebrictsl, A Phillips, Chaddesley Corbett
Journal: BMJ (1936)

Board, and, on the other, he could claim the honour of being a friend of Dr. George Buchan, in whom-the society had the best possible representative for its seat on the Central Midwives Board.That Board was indebted to the society and to a number of individual medical officers of health -for the observations submitted on the new training rules for pupil midwives.The Board had been able to adopt a large number of those suggestions, and considered, as a result, that its scheme had been materially improved.Rules with regard to refresher courses would be issued in the near future, and he felt confident that the Board would again receive the society's friendly co-operation.Medical officers of health could help a good deal, and he ventured to think that the Board might
Update: Universal Precautions for Prevention of Transmission of Human Immunodeficiency Virus, Hepatitis B Virus, and Other Bloodborne Pathogens in Health-Care Settings
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chemical Substance Transport in Soils and Its Effect on Groundwater Quality
Authors: Martin G. Khublarian
Journal: Environmental Health Perspectives (1989)

The problems of chemical substance applications in different spheres of industry and agriculture and their effects on groundwater quality and human health are described. Sources of groundwater contamination from industrial and municipal wastes, agricultural pollutants, etc., are listed. The experience in the application of chemical fertilizers and pesticides in the USSR is described. A brief estimation of groundwater salinity is given for various regions of the USSR where irrigation is practiced, as well as the experience in environmental protection. Special attention is given to methods of simulating water seepage and chemical substance transport in soils. Boundary problems for free-surface seepage and dissolved solids transport in porous media are stated, and methods of solution are described in the example of the hydrodynamic theory of seepage and dispersion. Some results of calculations with this method are presented. The influence of groundwater quality on the morbidity of the population is given and the main diseases and associated medical problems are listed.
The Modern Antipyretics; Their Action in Health and Disease.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Children's Blood Lead Levels in New Haven: A Population-Based Demographic Profile
Authors: Ruth Fitch Quah, Alice D. Stark, J. Wister Meigs, Edward R. DeLouise
Journal: Environmental Health Perspectives (1982)

This report presents the geometric mean blood lead levels of an 80% cross-sectional sample of children aged 1-72 months in New Haven, Connecticut. Blood lead levels were related to age, sex and race. It was found that age and race were independently important sources of variation in blood lead levels. Sex of children in this age group was not related to differences in blood lead levels. The highest geometric mean blood lead levels occurred in children between 25 and 36 months of age. Black children had higher levels than white or Hispanic children.
P2.01-17 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts
Authors: E. Felip, G. Castro, A. Greystoke, B. Solomon, D. Tan, V. Passos, S. Deudon, A. Louveau, B. Johnson
Journal: Journal of Thoracic Oncology (2019)
Somebody Likes Us
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Old age and new policy
Authors: D. Callahan
Journal: JAMA (1989)

IN THE fall of 1987, the Reagan administration announced a 35.8% increase in the monthly Medicare Part B premium for 1988. This increase, from $17.90 to $22.80, was the largest annual rise in the history of the program. An increase of that size would have been expected to draw an instant protest. However, while there were groans from the elderly and others, it was as if a new realism had set in that protest would, in any case, do little good. The simple truth is that health care for the elderly is expensive, that it will become even more so in the years ahead, and that no quick solution is at hand. Expenditures for the elderly under the Medicare program have increased at an inflationary rate of approximately 8% for the past few years; this is a rate twice the general pace of inflation. Despite almost two decades of trying,
Medicine and Nursing in the 1970s
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3448: Dasatinib attenuates Src pathway signaling and combined with veliparib and carboplatin potently inhibits tumor growth in a preclinical model of TNBC
Authors: Yuliang Sun, Xiaoqian Lin, Jennifer C. Aske, Casey Williams, Mark Abramovitz, Brian Leyland-Jones
Journal: Cancer Research (2019)

Abstract Background: The combination of a poly ADP ribose polymerase (PARP) inhibitor with a DNA-damaging agent has shown promise in treating triple-negative breast cancer (TNBC); however, not all patients respond to this combination (Rugo HS et al. The New England Journal of Medicine. 2016). The Src protein kinase modulates multiple cancer cell properties and plays a key role in tumorigenic processes. However, Src inhibitors as single agents have shown limited effects in solid tumors (Finn RS et al. Clinical Cancer Research. 2011). In this study, we examined the antitumor effects of the Src inhibitor dasatinib, the PARP inhibitor veliparib, and the DNA-damaging agent carboplatin in TNBC cells in vitro and tumors in vivo to try to identify the combination with the most clinical potential. Methods: The KRAS/BRAF-mutated TNBC cell line, MDA-MB-231, was used in this study. For in vitro studies, proliferation, cellular apoptosis, and 3D on-top clonogenic growth were measured, tube formation assays and western blot analysis were performed. For in vivo studies, a xenograft model was used to examine treatment responses, and immunohistochemical analysis was performed. Results: Surprisingly, treatment with the combination of veliparib plus carboplatin led to an increase in Src phosphorylation. Importantly, addition of dasatinib attenuated Src overexpression induced by veliparib plus carboplatin and further inhibited the downstream signaling of Src, thereby enhancing the antitumor efficacy of veliparib plus carboplatin. In an MDA-MB-231 xenograft model, the triple combination of dasatinib with veliparib plus carboplatin showed greater tumor growth inhibitory effects compared with single agents or double combinations. No systemic toxicity was observed in mice treated with the triple combination. Conclusions: Here, we provide novel evidence that veliparib combined with carboplatin drives Src activation in the preclinical model tested. Moreover, we provide provocative in vitro and in vivo data highlighting the potential for increasing therapeutic efficacy by combining dasatinib with veliparib and carboplatin in patients with KRAS/BRAF-mutated TNBC. Citation Format: Yuliang Sun, Xiaoqian Lin, Jennifer C. Aske, Casey Williams, Mark Abramovitz, Brian Leyland-Jones. Dasatinib attenuates Src pathway signaling and combined with veliparib and carboplatin potently inhibits tumor growth in a preclinical model of TNBC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3448.
Antibody studies claim awards spotlight
Authors: P. Gunby
Journal: JAMA (1984)

Five men—two of whom are physicians—received Albert Lasker Medical Research Awards this week. Two of the five recipients also will receive this year's Nobel Prize in Medicine and Physiology. The two Lasker Award recipients who also will become Nobel laureates are: Georges J. F. Köhler, PhD, 38, a native of West Germany who has been on the staff of the Basel (Switzerland) Institute for Immunology since 1976. He becomes one of three directors of the Max Planck Institute for Immune Biology, Freiburg, West Germany, later this year. He received his doctorate in biology from the University of Freiburg in 1974, then spent two years at the Laboratory of Molecular Biology, Cambridge, England, with César Milstein, PhD (see below), where—according to the Lasker Award citation—the two researchers developed "the first hybridoma and monoclonal antibody technology." César Milstein, PhD, 57, was born in Argentina, received his doctorate from Cambridge University in 1960,
Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy
Authors: J. Vidal, A. Dalmeses, C. Santos Vivas, R. Garcia-Carbonero, P. García-Alfonso, A. Carrato, E. Elez, M. Ortiz, F. Losa, B. Massutí, M. Valladares-Ayerbes, J. Manzano, J. Vieitez de Prado, J. Gallego, C. Grávalos, M. Varela, D. Azuara, J. Tabernero, R. Salazar, E. Aranda, B. Bellosillo, C. Montagut
Journal: Annals of Oncology (2018)

Introduction: Extended RAS and BRAF analysis is mandatory in metastatic colorectal cancer (mCRC) patients to establish the best therapeutic strategy. Recent studies aimed to determine the optimal threshold of RAS mutated subclones to identify patients most likely to benefit from anti-EGFR treatment (Laurent-Puig, CCR 2015; Santos C. Molec Can Ther 2017). Our aim is to assess the clinical relevance of highly sensitive Next Generation Sequencing (NGS) technology to detect point mutations in KRAS, NRAS, BRAF, and EGFR S492R in tissue tumor samples and its correlation with clinical outcome in terms of progression-free survival (PFS), overall response rate (ORR) and overall survival (OS) in mCRC patients treated with chemotherapy plus anti-EGFR or anti-VEGF therapy. Methods: 580 mCRC pre-treatment tumor tissue samples from retrospective series and clinical trials from TTD/RTICC Spanish network were collected. Mutational analysis was performed by pyrosequencing using NGS 454 GS Junior platform (Roche Applied Science, Mannheim, Germany), which reaches sensitivity below 1%. We defined two cutoff of mutant allele fraction (MAF) detection, 5% and 1%. Results: After quality assessment, 442 samples have been sequenced by Junior 454, and we have obtained enough coverage to evaluate the results from 380 samples. Using a 5% cutoff of sensitivity we detected RAS/BRAF mutations in 191 patients (49.77%) with a range MAF between 71.55% and 5.13%; 151 KRAS mutations (39.74%), 25 NRAS mutations (6.58%) and 13 BRAF mutations (3.42%). Using a 1% cutoff of sensitivity we detected 197 KRAS mutations (51.84%), 73 NRAS mutations (19.21%) and 24 BRAF mutations (6.32%). The lowest MAF detected was 1.02%. Patients all RAS/BRAF wt varied from 50.26% with a MAF cutoff of 5% to 22.63% with cutoff at 1%. As expected, the majority of tumors harbored mutations in KRAS exon 2 independently of cutoff used (83.44% and 83.25% in 5% and 1% respectively). No EGFR S492R mutations were detected in both cutoff thresholds. Patients follow-up is ongoing, correlation between mutational profile and clinical outcome will be presented. Conclusion: This study analyses the impact of using a NGS platform for molecular diagnosis of mCRC patients. Increasing the sensitivity of MAF cutoff from 5% to 1% we identified mutations in RAS/BRAF hotspots in 27.63% more patients. Confirming results from our previous reports, no mutations in EGFR ECD have been detected in untreated samples.
Cochlear implants
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 5554: Runx2 Represses TGFβ/Smad-Mediated Connective Tissue Growth Factor Gene Expression in Vascular Smooth Muscle Cells
Authors: Yoshiaki Ohyama, Toru Tanaka, Takehisa Shimizu, Hiroko Sato, Norimichi Koitabashi, Hiroshi Doi, Tatsuya Iso, Masashi Arai, Masahiko Kurabayashi
Journal: Circulation (2008)

[Background] Runx2, a key transcription factor for osteoblastic differentiation, is expressed in calcified atherosclerotic plaques. We recently reported that Runx2 represses vascular smooth muscle cells (VSMC) differentiation and promotes its osteogenic differentiation. Connective tissue growth factor (CTGF) has been implicated in the progression to vulnerable plaque by inducing mononuclear cell chemotaxis and VSMC apoptosis despite of its potent stimulatory effect on synthesis of extracellular matrix. In this study, we investigated the regulatory mechanism of CTGF gene expression by Runx2 in VSMC. [Methods and Results] RT-PCR analyses showed that adenovirally overexpressed Runx2 significantly repressed the basal expression of the CTGF gene in human aortic SMCs (HASMCs). Consistent with this, knockdown of the Runx2 expression in HASMCs by small interfering RNA (siRNA) increased CTGF mRNA levels. Luciferase assays showed that Runx2 reduced the transcriptional activity of the CTGF promoter. Transfection of a series of 5′-deletion constructs revealed that Runx2 inhibited CTGF expression through the sequence element located at 5′ untranslated region of CTGF mRNA. We next examined the effects of Runx2 on the TGFβ-induced CTGF expression. Runx2 overexpression significantly attenuated the TGFβ-mediated induction of CTGF expression in HASMCs, and knockdown of Runx2 by siRNA enhanced the induction of CTGF expression in response to TGFβ. Runx2 repressed TGFβ-induced CTGF promoter activity through the sequence containing Smad binding element (SBE), and luciferase assay using SBE-specific mutation construct showed that Runx2 repressed CTGF promoter activity in an SBE-dependent manner. Overexpression of Runx2 significantly reduced TGFβ and Smad3-mediated luciferase activity of 4xSBE-tkLuc, which contains four copies of SBE. Co-immunoprecipitation showed that Runx2 formed a complex with Smad4. [Conclusion] These data demonstrate that Runx2 represses basal and TGFβ-induced CTGF gene expression in VSMC, and thus suggest that besides the potential for inducing vascular calcification, Runx2 may affect plaque stability by modulating extracellular matrix synthesis through inhibiting CTGF gene expression and TGFβ signaling.
Error in Table.
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal